COPD stem cell therapy is still an area of research, not an approved treatment. The FDA has not approved any stem cell or regenerative product for chronic obstructive pulmonary disease, and studies so far are small or done in animals.
This page explains where the evidence stands, as a disease-specific companion to what is stem cell therapy. It is general education, not medical advice, and it does not suggest that any treatment helps any individual.
Why researchers study cell-based approaches in COPD
A 2022 systematic review in Cells describes COPD as an incurable disorder characterized by progressive destruction of alveolar tissue and defective mechanisms of repair and defense, leading to emphysema. The same review notes that current treatment is exclusively symptomatic. That gap is the reason researchers ask whether cells, or products derived from them, could limit or repair lung damage.
The idea is a research hypothesis. Lung tissue has a complex structure, and the question is not simply whether cells can be delivered to the lungs but whether they can change the course of a long-term disease in people. Most work so far has asked narrower questions: is the approach safe, and do any measurable signals appear in small groups of patients or in animal models.
What the FDA says about regulatory status
The FDA’s consumer information on regenerative medicine therapies states that these therapies have not been approved for the treatment of any cardiovascular or pulmonary diseases, such as heart disease, emphysema, or chronic obstructive pulmonary disease. The agency says that unapproved products offered outside a clinical trial for which it has oversight may be illegally marketed, and it lists safety concerns that include bacterial infections, unwanted immune responses and tumor formation.
The same FDA page, as of its 2024 update, states that the only stem cell products currently FDA-approved in the United States consist of blood-forming stem cells from umbilical cord blood, approved for disorders that affect blood production. On December 18, 2024, the FDA approved Ryoncil, a donor bone marrow-derived mesenchymal stromal cell therapy, for steroid-refractory acute graft-versus-host disease in children; the FDA’s list of approved cellular and gene therapy products is the current reference. Neither approval covers the lungs, and neither extends to lung disease.
What human studies have reported
The 2022 systematic review and meta-analysis in Cells pooled data from 371 COPD patients extracted from 11 studies. It reported that active treatments were associated with a significant increase in walking test distance of 52 m compared with baseline or control, and a trend in FEV1 that did not reach statistical significance. It also found that active treatments did not reduce the risk of hospitalization due to acute exacerbations.
The authors state that the current evidence comes from small clinical trials and that large and well-designed randomized controlled trials are needed to quantify any benefit. Pooling small studies that compare patients with their own earlier measurements, as well as with control groups, has well-known limits. Results can look larger than they prove to be in larger, blinded trials, and different studies used different cell types, doses and delivery routes.
For readers, the useful takeaway is the pattern rather than any single number: early signals in small studies, no effect on one important outcome, and an explicit call for better trials. That is the profile of an investigational approach, not a settled treatment.
What animal studies add
A 2026 systematic review and meta-analysis in Frontiers in Cell and Developmental Biology examined mesenchymal stromal cell transplantation in animal models that simulate COPD pathology, including emphysema and lung inflammation. It included 40 studies and reported improvements in alveolar structure and inflammatory markers in the animals.
The authors caution that differences in disease progression between animal models and human conditions are key factors for future clinical translation. The review itself frames its findings as a reference for the design of future preclinical studies and clinical trials.
How to read a COPD cell therapy study
Headlines about cell therapy often skip the details that decide how much a result means. A few questions help when reading any report in this area.
- Was the study in people or in animals? Animal findings guide trial design but do not show an effect in patients.
- Was there a control group, and were participants and clinicians blinded? Comparisons with a patient’s own earlier measurements are weaker evidence than comparisons with a control group.
- How many participants were followed, and for how long? Small, short studies cannot rule out chance or detect delayed harms.
- Which outcome improved, and did the outcomes that matter most to patients, such as hospital admissions for flare-ups, change?
- Was the product made and given under regulatory oversight, as in a registered clinical trial with FDA involvement?
Applied to the findings above, the human data come from small studies, the pooled analysis found no reduction in hospitalization, and the animal data come from models rather than patients. That combination explains why researchers and regulators describe the field as investigational.
Open questions for trials
Researchers still need to settle several practical questions before any cell product could be considered for COPD.
- Which cells. Studies have used different cell types and sources, which makes results hard to compare.
- Which route. Intravenous and airway delivery behave differently in animal work, and the best route in people is not established.
- Which dose and schedule. Animal data suggest dose matters, but human dosing has not been standardized.
- Which outcomes. Walking distance, lung function, exacerbations and quality of life can move differently, so trials need outcomes that matter to patients.
- How safe over time. Long-term follow-up is needed to detect delayed harms.
The same questions arise in other conditions. Readers can compare the status of stem cells for knee osteoarthritis and stem cell therapy for multiple sclerosis, where the pattern of small trials and unapproved products is similar.
Talking with a physician
COPD is a serious condition, and approved options exist for managing it. Decisions about any treatment, including whether a clinical trial is appropriate, belong with a licensed physician who knows the reader’s medical situation. The FDA asks anyone offered these products outside a clinical trial for which it has oversight to contact the agency, and says that being charged for them outside a trial suggests the product is being offered illegally.
Frequently asked questions
Is there an FDA-approved stem cell treatment for COPD?
Show answer
No. The FDA states that regenerative medicine therapies have not been approved for chronic obstructive pulmonary disease or other pulmonary diseases.
Have clinical studies of stem cells in COPD been done?
Show answer
Yes, mostly small ones. A 2022 meta-analysis pooled 11 of them and concluded that large, well-designed randomized controlled trials are still needed.
Do animal studies show that stem cells work for COPD?
Show answer
Animal studies report improvements in lung structure and inflammation in models, but the authors of a 2026 review note that animal models differ from human disease, so the results guide trial design rather than prove a human benefit.
What should someone ask if a clinic offers cells for lung disease?
Show answer
The FDA asks people offered these products outside a clinical trial under its oversight to contact the agency. Registration of a product or a ClinicalTrials.gov listing does not mean the product is legally marketed.
